As Dexcom seeks expanded coverage of its continuous glucose monitors (CGM) for people with Type 2 diabetes, it expects its Stelo users will shift. “What we hope for is that we can get insurance ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

That included stats showing Dexcom ... the FDA. Stelo’s features will also migrate to other systems, with the over-the-counter wearable acting as a gateway for people new to CGM as a whole.

In March 2024, the Food and Drug Administration cleared Dexcom’s Stelo as the ... Yet, despite the conceptual benefits of using continuous glucose monitoring for optimizing exercise, there ...

G6 continuous glucose monitor (CGM) receivers deliver glucose readings and alerts. However, certain devices may experience an ...

In August, DexCom announced the availability of Stelo, the first over-the-counter CGM biosensor in the United States for people with type II diabetes who do not use insulin. The expansion in the ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from ...

Second, DexCom has expanded its product offerings. Last year, it launched Stelo in the U.S., an over-the-counter CGM option that can be used by pre-diabetes patients. This initiative significantly ...

In August, DexCom announced the availability of Stelo, the first over-the-counter CGM biosensor in the United States for people with type II diabetes who do not use insulin. The expansion in the ...